# ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty

Study · id `cardio:ct-nct06611319` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06611319](<https://clinicaltrials.gov/study/NCT06611319>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06611319

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2932 participants.

## Technical summary

Registry record NCT06611319. Randomized; quadruple masking; primary purpose prevention. Start 2024-11-26 (actual); primary completion 2027-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 2932 participants (planned count; ClinicalTrials.gov record NCT06611319, source copy `cardio:ctgov-nct06611319-2025-01-16`, retrieved 2026-10-31)
- Started: 2024-11-26 (actual) (ClinicalTrials.gov record NCT06611319, source copy `cardio:ctgov-nct06611319-2025-01-16`, retrieved 2026-10-31)
- Primary completion: 2027-03 (anticipated) (ClinicalTrials.gov record NCT06611319, source copy `cardio:ctgov-nct06611319-2025-01-16`, retrieved 2026-10-31)
- Completion: 2027-07 (anticipated) (ClinicalTrials.gov record NCT06611319, source copy `cardio:ctgov-nct06611319-2025-01-16`, retrieved 2026-10-31)
- Countries: Austria; Germany (ClinicalTrials.gov record NCT06611319, source copy `cardio:ctgov-nct06611319-2025-01-16`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06611319-2025-01-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty
- Acronym: ENABLE-Hip
- Condition: Hip Arthroplasty, Total
- Condition: Prevention of Venous Thromboembolism
- Intervention (Drug): Prevention of Venous Thromboembolism
- Intervention (Drug): Placebo Oral Tablet
- Lead sponsor: Prof. Stavros Konstantinides, MD
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)

## Provenance

Content hash: c3bd036e68713be9fd73cfd17ba4178d2599dad23a3be9f3345a4eedb0de70a7
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
